Sernivo Approval History
- FDA approved: Yes (First approved February 5th, 2016)
- Brand name: Sernivo
- Generic name: betamethasone dipropionate
- Dosage form: Topical Spray
- Company: Promius Pharma, LLC
- Treatment for: Plaque Psoriasis
Sernivo Spray (betamethasone dipropionate) is a topical corticosteroid indicated for the treatment of mild to moderate plaque psoriasis.
The safety and efficacy of Sernivo Spray were evaluated in two double-blind clinical trials in which randomized subjects applied Sernivo Spray or vehicle spray to the affected areas twice daily for 28 days. At Day 29, Sernivo achieved treatment success of 42.7% and 34.5% compared to vehicle success rates of 11.7% and 13.6%, respectively.
Common side effects observed during clinical trials include pruritus, burning and/or stinging, pain, and atrophy at the application site.
Development History and FDA Approval Process for Sernivo
|Feb 7, 2016||Promius Pharma Receives FDA Approval for Sernivo (betamethasone dipropionate) Spray|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.